TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33605647

Group type: EXPERIMENTAL
Intervention: Qualitative interviews with family caregivers
Number of subjects: 39
Study: 33605887

Group type: EXPERIMENTAL
Intervention: ElderTree (ET) eHealth intervention for 12 months
Number of subjects: 346

Group type: COMPARATOR
Intervention: Usual care (UC) plus laptop and internet without ET
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: ElderTree (ET) eHealth intervention
Number of subjects: 346
Study: 33606006

Group type: COMPARATOR
Intervention: NOACs
Number of subjects: 52032

Group type: EXPERIMENTAL
Intervention: Minor bleeding
Number of subjects: 52032

Group type: EXPERIMENTAL
Intervention: CRNM bleeding
Number of subjects: 52032

Group type: EXPERIMENTAL
Intervention: Major bleeding
Number of subjects: 52032

Group type: EXPERIMENTAL
Intervention: Death within 30 days after major bleed
Number of subjects: 52032
Study: 33606061

Group type: EXPERIMENTAL
Intervention: Intraprocedural FDG perfusion PET
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Repeat ablation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Minimum ablation margins ≥ 5 mm on perfusion PET
Number of subjects: 20
Study: 33606142

Group type: EXPERIMENTAL
Intervention: Migraineurs (19 participants)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Healthy participants (19 participants)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Meta-analysis of published studies
Number of subjects: 38
Study: 33606269

Group type: EXPERIMENTAL
Intervention: CZP 400 mg Q2W
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: CZP 200 mg Q2W
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: CZP 400 mg Q2W and CZP 200 mg Q2W
Number of subjects: 127

Group type: COMPARATOR
Intervention: CZP 400 mg Q2W, CZP 200 mg Q2W, and placebo
Number of subjects: 127
Study: 33606312

Group type: EXPERIMENTAL
Intervention: Nasal allergen challenge (NAC) with cockroach extract (0.00381-11.9 µg/mL Bla g 1)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Nasal allergen challenge (NAC) with diluent
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Nasal allergen challenge (NAC)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Nasal allergen challenge (NAC) responders
Number of subjects: 25
Study: 33606413

Group type: EXPERIMENTAL
Intervention: Standard shock protocol with early invasive hemodynamic monitoring, mechanical circulatory support (MCS), and percutaneous coronary intervention (PCI)
Number of subjects: 300
Study: 33606418

Group type: EXPERIMENTAL
Intervention: Low tidal volume ventilation (LTVV), defined as VT of 8 ml kg-1 or less predicted bodyweight (PBW)
Number of subjects: 9864

Group type: EXPERIMENTAL
Intervention: Median tidal volume (VT)
Number of subjects: 9864

Group type: EXPERIMENTAL
Intervention: Factors mediating the sex difference in use of LTVV
Number of subjects: 9864
Study: 33606655

Group type: EXPERIMENTAL
Intervention: Medication management app delivered via care packages
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Framework for Agile and Remote Operations (FAR Ops)
Number of subjects: 21
Study: 33607083

Group type: EXPERIMENTAL
Intervention: Pulmonary arterial pruning
Number of subjects: 4227

Group type: EXPERIMENTAL
Intervention: Percent emphysema
Number of subjects: 4227
Study: 33607088

Group type: EXPERIMENTAL
Intervention: Anticoagulation ± antiplatelets in asymptomatic patients
Number of subjects: 52032

Group type: EXPERIMENTAL
Intervention: Anticoagulation ± antiplatelets in symptomatic patients
Number of subjects: 52032

Group type: COMPARATOR
Intervention: Asymptomatic patients
Number of subjects: 52032

Group type: COMPARATOR
Intervention: Symptomatic patients
Number of subjects: 52032
Study: 33607477

Group type: EXPERIMENTAL
Intervention: NBTXR3 (intratumoural injection) followed by intensity-modulated radiation therapy (IMRT; 70 Gy)
Number of subjects: 19
Study: 33607632

Group type: EXPERIMENTAL
Intervention: Pencil-beam scanning (PBS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive scattering (PS)
Number of subjects: 0
Study: 33607765

Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery (ERAS) program for LDG
Number of subjects: 98
Study: 33607957

Group type: EXPERIMENTAL
Intervention: Telehealth with remote blood pressure monitoring
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard outpatient monitoring
Number of subjects: 0
Study: 33608027

Group type: EXPERIMENTAL
Intervention: Non-invasive oocyte quality scoring based on cumulus gene expression analysis combined with morphology scoring (experimental arm, n=113)
Number of subjects: 633

Group type: COMPARATOR
Intervention: Morphology-based embryo selection only (control arm, n=520)
Number of subjects: 633
Study: 33608030

Group type: EXPERIMENTAL
Intervention: COVID-19-related ARDS
Number of subjects: 42

Group type: COMPARATOR
Intervention: Classical ARDS
Number of subjects: 42
Study: 33608053

Group type: EXPERIMENTAL
Intervention: Anti-BCMA CAR T cell therapy
Number of subjects: 1

Group type: COMPARATOR
Intervention: Lymphodepleting chemotherapy (LDC)
Number of subjects: 1
Study: 33608060

Group type: EXPERIMENTAL
Intervention: Buprenorphine treatment with measurement based care (MBC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TAPS tool for universal screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OUD Symptom Checklist and PAQ-OUD
Number of subjects: 0
Study: 33608263

Group type: EXPERIMENTAL
Intervention: Renin-Angiotensin-Aldosterone System Inhibitor (RAASi) Treatment
Number of subjects: 0
Study: 33608375

Group type: EXPERIMENTAL
Intervention: Single enhancer followed by VSV injection 1 day later for aggressively growing tumors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple enhancers followed by VSV injection 15 days later for slow-growing tumors
Number of subjects: 0
Study: 33608377

Group type: EXPERIMENTAL
Intervention: ABBV-428 administered intravenously every 2 weeks at doses between 0.01 and 3.6 mg/kg.
Number of subjects: 59
Study: 33608714

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 seropositive individuals
Number of subjects: 639

Group type: COMPARATOR
Intervention: SARS-CoV-2 seronegative individuals
Number of subjects: 639
Study: 33608748

Group type: EXPERIMENTAL
Intervention: Nobio Infinix composite (antibacterial composite)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control composite
Number of subjects: 20
Study: 33608798

Group type: EXPERIMENTAL
Intervention: Severe OSA (AHI ≥ 30)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Non-severe OSA (5 ≤ AHI ≤ 30)
Number of subjects: 49
Study: 33609152

Group type: EXPERIMENTAL
Intervention: Diagnostic ability of the intervention (not specified)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 15
Study: 33609856

Group type: EXPERIMENTAL
Intervention: 200 ug adjunctive estradiol treatment
Number of subjects: 56
Study: 33610169

Group type: EXPERIMENTAL
Intervention: Combined treatment with Habit Reversal Training (HRT) and Exposure Response Prevention (ERP)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Combined treatment with HRT and ERP (individual or group setting)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Combined treatment with HRT and ERP
Number of subjects: 59
Study: 33610319

Group type: EXPERIMENTAL
Intervention: IV carboplatin, paclitaxel, and bevacizumab every 21 days (regimen 1)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: Weekly IV paclitaxel with carboplatin and bevacizumab (regimen 2)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: IV paclitaxel and bevacizumab with IP cisplatin (regimen 3)
Number of subjects: 424

Group type: EXPERIMENTAL
Intervention: All regimens with veliparib (either continuous or intermittent)
Number of subjects: 424

Group type: COMPARATOR
Intervention: Not applicable (comparison of PFS)
Number of subjects: 424
Study: 33610453

Group type: EXPERIMENTAL
Intervention: Osimertinib plus platinum doublet (n=28)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Osimertinib plus single-agent chemotherapy (n=29)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Osimertinib plus chemotherapy
Number of subjects: 44
Study: 33610500

Group type: EXPERIMENTAL
Intervention: Haploidentical K562-mb15-41BBL-activated and expanded NK (NKAE) cells; 13 infusions administered after a lymphodepleting regimen
Number of subjects: 7
Study: 33610532

Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal dissection (ESD)
Number of subjects: 692
Study: 33611982

Group type: EXPERIMENTAL
Intervention: Plasma Hepatocyte Growth Factor (HGF) levels measured on day 1
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Plasma Hepatocyte Growth Factor (HGF) levels measured on day 3
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Correlation of HGF with endothelial cell injury markers
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: All-cause 28-day mortality
Number of subjects: 86
Study: 33612381

Group type: EXPERIMENTAL
Intervention: Blinded retrospective continuous glucose monitoring (rCGM)
Number of subjects: 102
Study: 33612455

Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg, every 3 weeks)
Number of subjects: 95
Study: 33613286

Group type: EXPERIMENTAL
Intervention: Immune checkpoint inhibitors
Number of subjects: 0
Study: 33613318

Group type: EXPERIMENTAL
Intervention: Standardized dietary fat intake (20 kcal⋅kgFFM)
Number of subjects: 0
Study: 33613417

Group type: EXPERIMENTAL
Intervention: Expanded Home-Based Telerehabilitation
Number of subjects: 0
Study: 33613422

Group type: EXPERIMENTAL
Intervention: Thrombolysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 33613701

Group type: EXPERIMENTAL
Intervention: PD-1 inhibitor monotherapy
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Combination of baseline lesion number (BLN) and tumor mutation burden (TMB)
Number of subjects: 58
Study: 33614477

Group type: EXPERIMENTAL
Intervention: Antiviral prophylaxis
Number of subjects: 170

Group type: COMPARATOR
Intervention: No antiviral prophylaxis (Control)
Number of subjects: 170
Study: 33614504

Group type: EXPERIMENTAL
Intervention: Combination of bortezomib, cyclophosphamide, and dexamethasone with daratumumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of bortezomib, cyclophosphamide, and dexamethasone without daratumumab
Number of subjects: 0
Study: 33614888

Group type: EXPERIMENTAL
Intervention: Rasagiline 1 mg daily for 24 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 33615207

Group type: EXPERIMENTAL
Intervention: NASH patients with pronounced insulin resistance (IR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: NASH patients
Number of subjects: 0
Study: 33615399

Group type: EXPERIMENTAL
Intervention: Macimorelin 0.5 mg/kg
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Macimorelin 0.75 mg/kg
Number of subjects: 28
Study: 33615630

Group type: EXPERIMENTAL
Intervention: Prucalopride (2 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 33615833

Group type: EXPERIMENTAL
Intervention: E-hookah vaping
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Ascorbic acid infusion
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sham-vaping control
Number of subjects: 26
Study: 33616178

Group type: EXPERIMENTAL
Intervention: Percutaneous peripheral nerve stimulation (PNS) for 60 days
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Percutaneous peripheral nerve stimulation (PNS) after 5 months
Number of subjects: 15
Study: 33616229

Group type: EXPERIMENTAL
Intervention: Xpert Ultra
Number of subjects: 3500

Group type: COMPARATOR
Intervention: Xpert MTB/RIF
Number of subjects: 3500
Study: 33616416

Group type: EXPERIMENTAL
Intervention: Intraperitoneal bevacizumab 2.5 mg/kg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Intraperitoneal bevacizumab 5 mg/kg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Intraperitoneal bevacizumab 7.5 mg/kg
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Intraperitoneal bevacizumab (all doses)
Number of subjects: 13
Study: 33616547

Group type: EXPERIMENTAL
Intervention: Getting Off app (immediate delivery, n=150)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Getting Off app (delayed delivery, n=150)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Historical matched sample (n=~600) from brick-and-mortar group-based Getting Off intervention
Number of subjects: 300
Study: 33616753

Group type: EXPERIMENTAL
Intervention: Isometric exercise (FM)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Concentric exercise (FM)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Isometric exercise (CON)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Concentric exercise (CON)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Both groups (FM and CON)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: FM
Number of subjects: 94
Study: 33616758

Group type: EXPERIMENTAL
Intervention: Pulse oximetry-derived peripheral perfusion index (PPI) after 200 mL crystalloid challenge
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Fluid challenge test using 200 mL crystalloid solution
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Additional 300 mL crystalloid infusion
Number of subjects: 58
Study: 33616875

Group type: EXPERIMENTAL
Intervention: Mid-mixture insulin analog (MMI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basal insulin (BI)
Number of subjects: 0
Study: 33617291

Group type: EXPERIMENTAL
Intervention: Biomechanical analysis during double-leg drop jump
Number of subjects: 1045

Group type: EXPERIMENTAL
Intervention: Biomechanical analysis during unplanned change of direction (CoD)
Number of subjects: 1045

Group type: COMPARATOR
Intervention: Commonly reported return-to-play strength, jump, and timed CoD performance measures
Number of subjects: 1045

Group type: EXPERIMENTAL
Intervention: Multivariate regression modeling
Number of subjects: 1045
Study: 33617672

Group type: EXPERIMENTAL
Intervention: DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1)
Number of subjects: 0
Study: 33617781

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33617813

Group type: EXPERIMENTAL
Intervention: Post-menopausal women
Number of subjects: 245

Group type: COMPARATOR
Intervention: Pre-menopausal women
Number of subjects: 245
Study: 33618265

Group type: EXPERIMENTAL
Intervention: Undernutrition (stunting or thinness)
Number of subjects: 1385

Group type: EXPERIMENTAL
Intervention: Median age of puberty onset for girls
Number of subjects: 1385

Group type: EXPERIMENTAL
Intervention: Median age of puberty onset for boys
Number of subjects: 1385

Group type: EXPERIMENTAL
Intervention: Age at first menarche for girls
Number of subjects: 1385

Group type: EXPERIMENTAL
Intervention: Nutrient deficiency
Number of subjects: 1385
Study: 33618437

Group type: EXPERIMENTAL
Intervention: Low-dose fludarabine and cyclophosphamide combined with rituximab (FCR); fludarabine reduced to 12 mg/m²
Number of subjects: 107
Study: 33618920

Group type: EXPERIMENTAL
Intervention: Hyperuricemic group (SUA ≥7 mg/dL in men and ≥6 mg/dL in women)
Number of subjects: 10537

Group type: EXPERIMENTAL
Intervention: Each increase in SUA
Number of subjects: 10537
Study: 33618925

Group type: EXPERIMENTAL
Intervention: MetS-related dietary pattern (MetS-DP) characterized by high intakes of processed meat and desserts, and low intakes of vegetables, tea, rice, fruits, milk, and meat substitutes
Number of subjects: 429
Study: 33619044

Group type: EXPERIMENTAL
Intervention: Rapid Cycling Work Rosters (RCWRs) with shifts ≤16 hours
Number of subjects: 294

Group type: COMPARATOR
Intervention: Extended-Duration Work Rosters (EDWRs) with shifts of 24+ hours
Number of subjects: 294
Study: 33619368

Group type: EXPERIMENTAL
Intervention: Anti-BCMA CAR T cell therapy
Number of subjects: 168

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 168
Study: 33619369

Group type: EXPERIMENTAL
Intervention: Daratumumab, carfilzomib, lenalidomide, and dexamethasone combination
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: CRISPR-Cas9 deletion of PPIA or inhibition of PPIA with ciclosporin
Number of subjects: 41
Study: 33619600

Group type: EXPERIMENTAL
Intervention: Radium-223 (55 kBq/kg, three administrations)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Radium-223
Number of subjects: 10
Study: 33619893

Group type: EXPERIMENTAL
Intervention: Clinically stable periods (CSP)
Number of subjects: 900
Study: 33619977

Group type: EXPERIMENTAL
Intervention: Adverse pregnancy outcomes/Gestational diabetes mellitus (APO/GDM)
Number of subjects: 4471
Study: 33620177

Group type: EXPERIMENTAL
Intervention: Cyclic treatment interruption (CTI) of rosuvastatin for 72 weeks (3 treatment-interruption cycles)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 10
Study: 33620327

Group type: EXPERIMENTAL
Intervention: imitoMeasure app
Number of subjects: 61

Group type: COMPARATOR
Intervention: acetate tracing
Number of subjects: 61
Study: 33620330

Group type: EXPERIMENTAL
Intervention: Mobile app (SweetGoals) with incentives for adherence
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Mobile app (SweetGoals) with web health coaching
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Mobile app (SweetGoals) as core intervention
Number of subjects: 300
Study: 33620373

Group type: EXPERIMENTAL
Intervention: Environmental factors (precipitation, temperature, relative humidity)
Number of subjects: 114067

Group type: EXPERIMENTAL
Intervention: Environmental factors (precipitation)
Number of subjects: 114067

Group type: EXPERIMENTAL
Intervention: Warm and wet environments
Number of subjects: 114067
Study: 33620378

Group type: EXPERIMENTAL
Intervention: Perioperative screening for postoperative MACE with serial measurements of cardiac troponin
Number of subjects: 2265

Group type: EXPERIMENTAL
Intervention: CVD
Number of subjects: 2265

Group type: EXPERIMENTAL
Intervention: Haemodynamically relevant arrhythmias
Number of subjects: 2265

Group type: EXPERIMENTAL
Intervention: AHF
Number of subjects: 2265

Group type: EXPERIMENTAL
Intervention: Spontaneous MI
Number of subjects: 2265

Group type: EXPERIMENTAL
Intervention: PMI
Number of subjects: 2265
Study: 33620434

Group type: EXPERIMENTAL
Intervention: Prior CABG
Number of subjects: 4015
Study: 33620451

Group type: EXPERIMENTAL
Intervention: Management conservatively (89% of older patients)
Number of subjects: 318

Group type: EXPERIMENTAL
Intervention: Older patients with SCAD
Number of subjects: 318
Study: 33620559

Group type: EXPERIMENTAL
Intervention: PSMA-PET/MRI
Number of subjects: 42
Study: 33620690

Group type: EXPERIMENTAL
Intervention: Vitamin D
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Fatty Acid Profile
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ω6:Ω3 Ratio
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: DHA and EPA Levels
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Zinc Oxide Concentration
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cupric Oxide Deficiency
Number of subjects: 50
Study: 33620705

Group type: EXPERIMENTAL
Intervention: Presence of EDCs in follicular fluid
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: EDC exposure
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: EDC concentration
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Patients' lifestyle factors
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Residential area, source of food products, nicotine or caffeine consumption
Number of subjects: 210
Study: 33620904

Group type: EXPERIMENTAL
Intervention: Single purified exosome product (PEP) injection (acute-single)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Weekly PEP injections (acute-weekly, 4 total injections)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Delayed single injection (subacute-single)
Number of subjects: 6
Study: 33620906

Group type: EXPERIMENTAL
Intervention: Mirror during pelvic examination
Number of subjects: 145

Group type: COMPARATOR
Intervention: No mirror during pelvic examination
Number of subjects: 145
Study: 33620918

Group type: EXPERIMENTAL
Intervention: MemoryGel Breast Implants (primary augmentation)
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: MemoryGel Breast Implants (revision augmentation)
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: MemoryGel Breast Implants (primary reconstruction)
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: MemoryGel Breast Implants (revision reconstruction)
Number of subjects: 1008
Study: 33621442

Group type: EXPERIMENTAL
Intervention: HHe-3 MRI
Number of subjects: 60
Study: 33621600

Group type: EXPERIMENTAL
Intervention: Inhaled amikacin-containing multidrug regimens (including IV amikacin, imipenem or cefoxitin, oral azithromycin, and oral clofazimine if applicable)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Inhaled amikacin-containing multidrug regimens
Number of subjects: 82
Study: 33621837

Group type: EXPERIMENTAL
Intervention: Self-management training for VAD patients
Number of subjects: 20
Study: 33621908

Group type: EXPERIMENTAL
Intervention: fMRI False Belief task
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Hinting Task
Number of subjects: 53
Study: 33621914

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral based group psychotherapy (CBGP), n = 25
Number of subjects: 47

Group type: COMPARATOR
Intervention: Delayed treatment control group (DTCG), n = 22
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral based group psychotherapy (CBGP)
Number of subjects: 47
Study: 33622344

Group type: EXPERIMENTAL
Intervention: MERLIN robotic system for upper limb rehabilitation
Number of subjects: 9
Study: 33622371

Group type: EXPERIMENTAL
Intervention: High TIL treatments (metabolic suppression, hypothermia (< 35 °C), intensive hyperventilation)
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: High TIL treatments
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: High TIL treatments after day 1
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: Metabolic suppression at any day
Number of subjects: 758
Study: 33622393

Group type: EXPERIMENTAL
Intervention: Postoperative pain measured at 0 h, 3 h, 6 h, 12 h, 24 h, 48 h, and 3 months after surgery
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Axillary surgery
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Preoperative use of pain medications
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Higher dynamic NRS values at 6 h postoperatively
Number of subjects: 307
Study: 33622508

Group type: EXPERIMENTAL
Intervention: Integrated treatment program (3 to 5 in-person sessions + weekly phone calls supported by a mobile app)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Integrated treatment program
Number of subjects: 33
Study: 33623980

Group type: EXPERIMENTAL
Intervention: EXimpaired group (n=20)
Number of subjects: 53

Group type: COMPARATOR
Intervention: EXadequate group (n=18)
Number of subjects: 53